These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 4040467

  • 1. Striatal dopamine receptor sensitivity after subchronic fencamfamine in the rat.
    Scavone C, De Lucia R, Bernardi MM, Aizenstein ML.
    Eur J Pharmacol; 1985 May 28; 112(1):11-6. PubMed ID: 4040467
    [Abstract] [Full Text] [Related]

  • 2. On the mechanism which mediates the effects of long-term administration of fencamfamine in rats.
    Planeta CS, DeLucia R, Aizenstein ML, Scavone C.
    Braz J Med Biol Res; 1989 May 28; 22(7):881-3. PubMed ID: 2576524
    [Abstract] [Full Text] [Related]

  • 3. Behavioural effects of long-term administration of fencamfamine: neurochemical implications.
    Planeta CS, Scavone C, De Lucia R, Aizenstein ML.
    Gen Pharmacol; 1987 May 28; 18(4):347-9. PubMed ID: 3609692
    [Abstract] [Full Text] [Related]

  • 4. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
    Hall MD, Cooper DR, Fleminger S, Rupniak NM, Jenner P, Marsden CD.
    Neuropharmacology; 1984 May 28; 23(5):545-53. PubMed ID: 6539859
    [Abstract] [Full Text] [Related]

  • 5. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
    Nomura Y, Komori T, Okuda S, Segawa T.
    Arch Int Pharmacodyn Ther; 1979 Jan 28; 237(1):25-30. PubMed ID: 485682
    [Abstract] [Full Text] [Related]

  • 6. Comparative biochemical and behavioural effects of fencamfamine and dl-amphetamine in rats.
    Aizenstein ML, Scavone C, Bernardi MM, Delucia R.
    Prog Neuropsychopharmacol Biol Psychiatry; 1983 Jan 28; 7(2-3):187-94. PubMed ID: 6684314
    [Abstract] [Full Text] [Related]

  • 7. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
    Boyce S, Kelly E, Davis A, Fleminger S, Jenner P, Marsden CD.
    Biochem Pharmacol; 1985 May 15; 34(10):1665-9. PubMed ID: 2988552
    [Abstract] [Full Text] [Related]

  • 8. Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months.
    Clow A, Jenner P, Theodorou A, Marsden CD.
    Nature; 1979 Mar 01; 278(5699):59-61. PubMed ID: 570253
    [No Abstract] [Full Text] [Related]

  • 9. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.
    Magnusson O, Fowler CJ, Köhler C, Ogren SO.
    Neuropharmacology; 1986 Feb 01; 25(2):187-97. PubMed ID: 2939362
    [Abstract] [Full Text] [Related]

  • 10. The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum.
    Walters DE, Howard SG.
    Eur J Pharmacol; 1990 Aug 10; 184(2-3):257-64. PubMed ID: 2150376
    [Abstract] [Full Text] [Related]

  • 11. Cytidine(5')diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine.
    Agut J, Coviella IL, Wurtman RJ.
    Neuropharmacology; 1984 Dec 10; 23(12A):1403-6. PubMed ID: 6543245
    [Abstract] [Full Text] [Related]

  • 12. Chronic antidepressant administration fails to attenuate apomorphine-induced decreases in rat striatal dopamine metabolites.
    Diggory GL, Buckett WR.
    Eur J Pharmacol; 1984 Oct 15; 105(3-4):257-63. PubMed ID: 6510470
    [Abstract] [Full Text] [Related]

  • 13. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation.
    Carvey PM, Hitri A, Goetz CG, Tanner CM, Klawans HL.
    Life Sci; 1988 Oct 15; 42(22):2207-15. PubMed ID: 3374255
    [Abstract] [Full Text] [Related]

  • 14. Striatal dopamine metabolism in response to apomorphine: the effects of repeated amphetamine pretreatment.
    Kuczenski R, Leith NJ, Applegate CD.
    Brain Res; 1983 Jan 10; 258(2):333-7. PubMed ID: 6824917
    [Abstract] [Full Text] [Related]

  • 15. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O, Roncada P, Dall'Olio R, Montanaro N.
    Brain Res; 1988 Jul 12; 455(2):390-3. PubMed ID: 2969768
    [Abstract] [Full Text] [Related]

  • 16. During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated.
    Dyer RG, Murugaiah K, Theodorou A, Clow A, Jenner P, Marsden CD.
    Life Sci; 1981 Jan 12; 28(2):167-74. PubMed ID: 6114373
    [No Abstract] [Full Text] [Related]

  • 17. Subchronic cocaine treatment enhances cocaine-induced dopamine efflux, studied by in vivo intracerebral dialysis.
    Akimoto K, Hamamura T, Otsuki S.
    Brain Res; 1989 Jun 26; 490(2):339-44. PubMed ID: 2765867
    [Abstract] [Full Text] [Related]

  • 18. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD.
    Clin Neuropharmacol; 1984 Jun 26; 7(3):247-57. PubMed ID: 6435870
    [Abstract] [Full Text] [Related]

  • 19. Alteration of striatal dopaminergic functions implicated in methamphetamine-induced reverse tolerance in rats.
    Kaneno S, Watanabe A, Takahashi R.
    Eur J Pharmacol; 1986 Apr 16; 123(2):287-94. PubMed ID: 3086109
    [Abstract] [Full Text] [Related]

  • 20. Apomorphine enantiomers' effects on dopamine metabolism: receptor and non-receptor related actions.
    Saller CF, Salama AI.
    Eur J Pharmacol; 1986 Feb 18; 121(2):181-8. PubMed ID: 3699091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.